AbobotulinumtoxinA - Ultrasound-Guided Technique

Phase 3

AbobotulinumtoxinA - Ultrasound-Guided Technique is one of 4 therapeutic programs targeting Spastic paraplegia. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Spastic ParaplegiaRecruiting

Spastic ParaplegiaPhase 3

Recruiting

Competition

Competitive Landscape

4 competitors in Spastic Paraplegia

#DrugCompanyPhaseTrials

Lipitor

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Approved

—2

AbobotulinumtoxinA - Ultrasound-Guided Technique

UUniversidade Federal Fluminense

Phase 3

1 3

Calcium Folinate

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 1

1 4

MELPIDA

EElpida Therapeutics SPC

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

ApprovedRecruiting

Spastic Paraplegia

NCT07803276

Clinical

Trials by Indication[1]

Spastic paraplegia1 trial

Comparison Between Palpatory and Ultrasound-guided Methods for Botulinum Toxin Administration in Spastic Paraplegia

Recruiting·UUniversidade Federal Fluminense·Approved·NCT07803276·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for AbobotulinumtoxinA - Ultrasound-Guided Technique. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for AbobotulinumtoxinA - Ultrasound-Guided Technique. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Universidade Federal Fluminense company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversidade Federal Fluminense

AbobotulinumtoxinA - Ultrasound-Guided Technique

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Spastic paraplegia1 trial

References

Drug Info

Quick Facts

Related News